Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;18(1):25-36.
doi: 10.1007/s40256-017-0249-9.

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Christian J F Holubarsch  1 , Wilson S Colucci  2 , Jaan Eha  3
Affiliations
Review

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Christian J F Holubarsch et al. Am J Cardiovasc Drugs. 2018 Feb.

Abstract

Preparations from Crataegus (hawthorn) have a long history in the treatment of heart failure. WS 1442 is a dry extract from hawthorn leaves with flowers (4-6.6:1), extraction solvent of ethanol 45% (w/w), adjusted to 17.3-20.1% of oligomeric procyanidins. Nonclinical studies show that WS 1442 has positive inotropic and antiarrhythmic properties and protects the myocardium from ischemic damage, reperfusion injury, and hypertension-related hypertrophy, improves endothelial functions such as NO synthesis, and delays endothelial senescence. Randomized, controlled trials in patients with heart failure have demonstrated that the herbal medicinal product increases functional capacity, alleviates disabling symptoms, and improves health-related quality of life, all of which have become important targets of heart failure therapy according to current disease management guidelines. Clinical trials (including a 2-year mortality study with polypharmacy and > 1300 patients exposed) and post-marketing surveillance studies have shown that WS 1442 has a very favorable safety profile both as monotherapy and as add-on therapy, where no drug interactions have been observed. No specific adverse reactions to WS 1442 are known to date. WS 1442 may thus help to close the therapeutic gap between systolic and diastolic heart failure for which evidence of efficacy for other cardioactive drugs is sparse. Scientific evidence shows that WS 1442 is safe and has a beneficial effect in patients with heart failure corresponding to New York Heart Association classes II or III. The benefit-risk assessment for WS 1442 is therefore positive.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

CJFH, WSC and JE have received honoraria from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany for conducting, and writing for, the SPICE study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the studies.

Figures

Fig. 1
Fig. 1
Cumulative hazard for time to first cardiac event (from [40])
Fig. 2
Fig. 2
Cumulative hazard for cardiac mortality (a, c) and sudden cardiac death (b, d): all patients (a, b) or patients with LVEF ≥ 25% (c, d) (from [40]). LVEF left ventricular ejection fraction
Fig. 3
Fig. 3
Cardiac mortality and sudden cardiac death in total population and subgroup LVEF ≥ 25% (hazard ratios, 95% confidence intervals and two-sided log-rank test p values) (from [40]). LVEF left ventricular ejection fraction
Fig. 4
Fig. 4
Maximum workload (W): meta-analysis of difference between Crataegus and placebo for change from baseline (means and 95% confidence intervals, random effects model) Data from [52], Fig. 1.1, based on studies reported by Bödigheimer and Chase [53] (LI 132), Hanak and Brückel [54], Tauchert [37] and Zapfe [55] (all WS 1442)
Fig. 5
Fig. 5
Time for 2-km walking test (means and standard deviations; data from [45])
Fig. 6
Fig. 6
Reduction in the total score of von Zerssen Complaints (means, standard deviations, and two-sided p values; from [37], Fig. 4, and [81])
Fig. 7
Fig. 7
Average change in frequency and intensity of heart failure symptoms assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ) (from [45], Fig. 4)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Inman T. Foundation for a new theory and practice of medicine. London: John Churchill; 1860.
    1. Sokol DK. “First do no harm” revisited. BMJ. 2013;347:f6426. doi: 10.1136/bmj.f6426. - DOI - PubMed
    1. Der Weißdorn Kaul R. Botanik, Inhaltsstoffe, Qualitätskontrolle, Pharmakologie, Toxikologie und Klinik. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1998.
    1. Jennings MC. Crataegus oxyacantha in the treatment of heart disease. N Y Med J. 1896;10(10):491–3.
    1. Bundesgesundheitsamt. Monographie—Crataegi folium cum flore (Weißdornblätter mit Blüten). Bundesanzeiger. 1994;133 (19 July 1994):7360–1.

MeSH terms